Skip Navigation

European Heart Journal 1986 7(1):4-13;
Copyright © 1986 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by VERSTRAETE, M.
Right arrow Articles by SLEIGHT, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by VERSTRAETE, M.
Right arrow Articles by SLEIGHT, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1986 The European Society of Cardiology

Evaluation of antiplatelet agents in the prevention of aorto-coronary bypass occlusion*

M. VERSTRAETE, B. G. BROWN, J. H. CHESEBRO, S. EKESTRÖM, L. A. HARKER, A. H. HENDERSON, D. E. JEWITT, M. F. OLIVER and P. SLEIGHT

Received 25 August 1985; .

Prof. M. Verstraete, Centre for Thrombosis and Vascular Research, University of Leuven, Campus Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium

Abstract

The cumulative occlusion rates of aorto-coronary artery venous bypass grafts average from 16 to 26% per distal anastomosis within 12 months and about 2% per following year. The potential benefit of oral anticoagulants and platelet inhibitor drugs has been tested to prevent graft occlusion and to retard the atherosclerotic process.

Oral anticoagulants started on the third postoperative day do not significantly reduce graft occlusion after 6 months. Among the platelet inhibitor drugs, dipyridamole started before surgery, followed by dipyridamole and aspirin soon after surgery, was the drug regimen with the best results.

More randomised double-blind clinical trials are highly desirable to confirm these findings and to resolve the question of relative efficacy and safety for the various drugs reported to have shown benefit when used in combination.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Immunol.Home page
C. A. Bursill, J. L. Cash, K. M. Channon, and D. R. Greaves
Membrane-Bound CC Chemokine Inhibitor 35K Provides Localized Inhibition of CC Chemokine Activity In Vitro and In Vivo
J. Immunol., October 15, 2006; 177(8): 5567 - 5573.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
B. S. Donahue
Factor V Leiden and Perioperative Risk
Anesth. Analg., June 1, 2004; 98(6): 1623 - 1634.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
E. Lim, Z. Ali, A. Ali, T. Routledge, L. Edmonds, D. G Altman, and S. Large
Indirect comparison meta-analysis of aspirin therapy after coronary surgery
BMJ, December 6, 2003; 327(7427): 1309.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.